CCP
ACAD icon

Corient Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Corient Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,542
Closed -$207K – 689
2022
Q1 		$207K Buy
+8,542
New +$207K 0.01% 675

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Corient Capital Partners's ACAD Position: Q2 2022 in Review

Corient Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 8,542 shares — an estimated $207K sold.

Corient Capital Partners first reported a position in ACAD in Q1 2022 and held it in 1 quarter. The position peaked at $207K in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Corient Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Corient Capital Partners sold 8,542 Acadia Pharmaceuticals shares in Q2 2022, an estimated $207K.
  • Corient Capital Partners first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Corient Capital Partners's Acadia Pharmaceuticals position peaked at $207K in Q1 2022.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.